Cancer Drug Responses Camp Lejeune NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

James Earl Radford
(828) 692-8045
1824 Pisgah Drive
Hendersonville, NC
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Gregory Lee Jones, MD
(828) 879-7536
2203 S Sterling St
Morganton, NC
Specialties
Oncology (Cancer), Radiation Oncology, Internal Medicine
Gender
Male
Education
Medical School: Med Coll Of Ga Sch Of Med, Augusta Ga 30912
Graduation Year: 1984

Data Provided by:
Carolyn Sartor, MD
(919) 966-7700
CB 7512,
Chapel Hill, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Female
Education
Medical School: Univ Of Mi Med Sch, Ann Arbor Mi 48109
Graduation Year: 1992

Data Provided by:
Robert Carr Moffatt, MD
(828) 258-2464
86 Victoria Rd
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Tn, Memphis, Coll Of Med, Memphis Tn 38163
Graduation Year: 1957
Hospital
Hospital: St Josephs Hospital, Asheville, Nc
Group Practice: Western Surgical Ctr

Data Provided by:
Edward S Baum, MD
(704) 341-3054
4118 Waterford Dr
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Allen Russell Chauvenet, MD
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Fl Coll Of Med, Gainesville Fl 32610
Graduation Year: 1978

Data Provided by:
Charles Walter Scarantino
(919) 784-3018
4420 Lake Boone Trl
Raleigh, NC
Specialty
Radiation Oncology

Data Provided by:
Gail A Leget, MD
(910) 671-5760
1200 Pine Run Dr
Lumberton, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Ecole Libre De Med, Lille, France
Graduation Year: 1991

Data Provided by:
David L Williams
(910) 692-2061
400 Nw Broad St
Southern Pines, NC
Specialty
Hematology / Oncology

Data Provided by:
Mohan Chand Thakuri, MD
(336) 716-5257
Watlington Hall 1st Fl Medcl Ctr Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Tribhuvan Univ, Inst Of Med, Kathmandu, Nepal
Graduation Year: 1991

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com